| Volume: | 5,495,396 |
|---|---|
| Day's Low: | $53.87 |
| 52-wk Low: | $44.96 |
| Previous Close: | $54.05 |
| Dividend: | $0.00 |
| Market Cap: | 55,536,400 |
| Avg Volume: | 7,077,600 |
|---|---|
| Day's High: | $54.94 |
| 52-wk High: | $64.76 |
| Open Price: | $53.87 |
| Yield: | 0.00% |
| P/E (Forward): | 11.05 |
| 1:06 PM | 11/5/2009 | Amgen's Vectibix Misses Survival Goal,But Sales Could Benefit |
| 3:28 PM | 10/30/2009 | CORRECT: NY AG: 14 States, DC Sue Amgen Over Alleged Kickback Scheme |
| 3:03 PM | 10/30/2009 | AmerisourceBergen: Has Received Subpoena In Amgen Lawsuit-Fox Business |
| 8:53 AM | 10/22/2009 | UPDATE: BEFORE THE BELL -2: US HOT STOCKS TO WATCH |
| 6:30 AM | 10/22/2009 | BEFORE THE BELL -2: US HOT STOCKS TO WATCH |
| 7:00 PM | 10/21/2009 | 2nd UPDATE: Amgen 3Q Profit Up 24%; FDA Seeks Bone Drug Info |
| 5:57 PM | 10/21/2009 | UPDATE: Amgen 3Q Profit Up 24%; FDA Seeks Info On Bone Drug |
| 11/2/2009 | Biotech Blues a Blip? |
| 10/30/2009 | States Sue Amgen Over Sales Practices |
| 10/30/2009 | 14 states sue Amgen over alleged kickbacks |
| 10/30/2009 | Amgen Hit With Suit Alleging Kickbacks Over Anemia Drug |
| 10/28/2009 | Cause for a Pause, or Perhaps Worse for Stocks |
| 10/24/2009 | Charting The Market |
| 10/23/2009 | Two Top Ideas in Biotech |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.49 | 1.21 | 23.14 |
| EPS, GAAP | 1.36 | 1.09 | 24.77 |
| Consensus Estimate | 1.25 | 1.06 | 17.92 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 4.88 | 4.48 | 8.93 |
| EPS, GAAP | 4.22 | 3.76 | 12.23 |
| Consensus Estimate | 4.57 | NA | NA |
| AMGN | Industry Average | |
| P/E (TTM) | 12.96 | 185.00 |
| P/E (Forward) | 11.05 | -21.30 |
| PEG Ratio | 1.02 | -1.08 |
| Price/Sales | 3.80 | 4.67 |
| Beta | 0.53 | 0.38 |